Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Leiner & loratadine

This article was originally published in The Tan Sheet

Executive Summary

Company's "goal is to create marketing programs to enable [its loratadine] retail private label sales to exceed 30% of the market," which it anticipates "to be $500 mil.," firm says. Leiner expects to ship its generic version of Schering-Plough's OTC Claritin in mid-July (1"The Tan Sheet" Feb. 10, 2002, p. 8). Company notes it will support initial loratadine offering by conducting "in-store promotions and regional advertising in conjunction with [its] retail consumers." Leiner will consider manufacturing, marketing other forms of loratadine at a later date, firm adds, noting that, overall, it expects "to introduce into the market new innovative products...that will generate $100 mil. in gross sales" in 2003...

You may also be interested in...

Leiner Store Brand Loratadine To Begin Retail Shipments In July

Leiner Health Products plans to begin shipping private label OTC loratadine immediate-release 10 mg tablets "on or around" July 21, according to the firm

In Comments And In Person, Pharmacist Groups Remind US FDA They'll Provide ACNU Help

Pharmacist groups’ representatives, in meeting with FDA officials, reiterate argument for greater role in access to OTCs through “additional conditions for nonprescription use.” Group not at meeting, American Society of Health-System Pharmacists, suggests “intermediate approach to nonprescription status.”

‘Fail First’ Requirement In ACNU Proposal Prompts Adverse Reactions Across US Drug Industry

PhRMA captures tone of its comments saying “proposed rule might play an important role” in making more drugs available OTC. AAM also references gauntlet, saying proposed pathway “would, in theory, broaden the types of nonprescription drugs available to consumers.” CHPA discusses same concerns as well as additional questions for FDA.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts